LB Pharmaceuticals Inc Common Stock (LBRX) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -23.29M | -18.1M | -3.37M | -6.87M | -8.13M | -9.57M |
| Operating CF Margin % | - | - | - | - | - | - |
| Operating CF Growth % | -186.54% | - | - | - | 15.09% | - |
| Net Income | -19.05M | -11.47M | -3.56M | -5.09M | -5.31M | -16.15M |
| Depreciation & Amortization | 82K | 85K | 81K | 77.5K | 79K | 3K |
| Stock-Based Compensation | 0 | 0 | 881K | 484.5K | 0 | 73K |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 2.43M | 2.81M | -682K | -2.55M | -132K | 154K |
| Working Capital Changes | -6.75M | -9.53M | -97K | 211K | -2.77M | 6.35M |
| Change in Receivables | 103K | -100K | -208K | 0 | 40K | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 3.46M | 1.97M | 0 | 0 | -2.89M | 0 |
| Cash from Investing | -32K | -40K | -44.84M | 2.49M | 4.98M | -26.06M |
| Capital Expenditures | -32K | -40K | 0 | -6K | -21K | -47K |
| CapEx % of Revenue | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 2.5M | 0 | 0 |
| Cash from Financing | 93.83M | -1.17M | 303.73M | 0 | 0 | 38.29M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 93.83M | -1.17M | 247K | 0 | 0 | 40M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 0 | 0 | 303.49M | 0 | 0 | -1.71M |
| Net Change in Cash | 70.5M | -19.57M | 255.52M | 0 | 0 | 2.65M |
| Free Cash Flow | -23.32M | -18.14M | -3.37M | -6.87M | -8.15M | -9.62M |
| FCF Margin % | - | - | - | - | - | - |
| FCF Growth % | -186.19% | - | - | - | 15.29% | - |
| FCF per Share | -0.83 | -0.72 | -0.13 | -27.29 | -32.36 | -2.72 |
| FCF Conversion (FCF/Net Income) | 1.22x | 1.58x | 0.95x | 1.35x | 1.60x | 0.59x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 |